UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 288

Sortiert nach

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

European respiratory review, 2017-12, Vol.26 (146), p.170057

2017

Volltextzugriff (PDF)

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Respiratory research, 2020-02, Vol.21 (1), p.48-48, Article 48

2020

Volltextzugriff (PDF)

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management

Advances in therapy, 2019-02, Vol.36 (2), p.298-317

2019

Volltextzugriff (PDF)

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2017-09, Vol.196 (6), p.756-761

2017

Volltextzugriff (PDF)

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2017-09, Vol.196 (6), p.756-761

2017

Volltextzugriff (PDF)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

The European respiratory journal, 2018-08, Vol.52 (2), p.1800230

2018

Volltextzugriff (PDF)

FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change

The European respiratory journal, 2020-05, Vol.55 (5), p.1902151

2020

Volltextzugriff (PDF)

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment

Respiratory medicine, 2019-07, Vol.153, p.44-51

2019

Volltextzugriff (PDF)

Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control

Chest, 2005-10, Vol.128 (4), p.1910-1920

2005

Volltextzugriff (PDF)

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Pulmonary therapy, 2018-06, Vol.4 (1), p.103-114

2018

Volltextzugriff (PDF)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

Pulmonary therapy, 2018-06, Vol.4 (1), p.59-71

2018

Volltextzugriff (PDF)

Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons

Expert review of respiratory medicine, 2021-02, Vol.15 (2), p.175-181

2021

Volltextzugriff (PDF)

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Advances in therapy, 2019-10, Vol.36 (10), p.2910-2926

2019

Volltextzugriff (PDF)

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

ERJ open research, 2018-10, Vol.4 (4), p.84

2018

Volltextzugriff (PDF)

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Advances in therapy, 2019-10, Vol.36 (10), p.2927-2929

2019

Volltextzugriff (PDF)

Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis

Chronic respiratory disease, 2019, Vol.16, p.1479973119879678-1479973119879678

2019

Volltextzugriff (PDF)

Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control

Chest, 2005-10, Vol.128 (4), p.1910

2005

Volltextzugriff (PDF)

The human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer

Oncogene, 2005-07, Vol.24 (31), p.4873-4882

2005

Volltextzugriff (PDF)

Do autopsies of critically ill patients reveal important findings that were clinically undetected?

Critical care medicine, 1998-08, Vol.26 (8), p.1332-1336

1998

Volltextzugriff (PDF)

Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol

Journal of allergy and clinical immunology, 2006-07, Vol.118 (1), p.44-52

2006

Volltextzugriff (PDF)

Transbronchial biopsy with virtual CT bronchoscopy and nodal highlighting

Radiology, 2001-11, Vol.221 (2), p.531

2001

Volltextzugriff (PDF)

Montelukast added to fluticasone propionate does not alter inflammation or outcomes

Respiratory medicine, 2010-10, Vol.104 (10), p.1425-1435

2010

Volltextzugriff (PDF)

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2017-09, Vol.196 (6), p.756

2017

Volltextzugriff (PDF)

Survival Following Mechanical Ventilation for Acute Respiratory Failure in Adult Men

Chest, 1993-10, Vol.104 (4), p.1222-1229

1993

Volltextzugriff (PDF)

Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol

Journal of allergy and clinical immunology, 2006-07, Vol.118 (1), p.44

2006

Volltextzugriff (PDF)

1 – 25 von 288

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(252)
Mit Volltextzugriff
(253)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment

Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis

Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control

The human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer

Do autopsies of critically ill patients reveal important findings that were clinically undetected?

Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol

Transbronchial biopsy with virtual CT bronchoscopy and nodal highlighting

Montelukast added to fluticasone propionate does not alter inflammation or outcomes

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

Survival Following Mechanical Ventilation for Acute Respiratory Failure in Adult Men

Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol

Suchergebnisse filtern